Pasireotide
Pasireotide is a second-generation somatostatin analogue that hits more receptor types than octreotide. It is approved for Cushing's disease and acromegaly caused by pituitary tumours when surgery has not cured them, at the cost of frequent high blood sugar.
Overview
Pasireotide (SOM230) was developed by Novartis and is now marketed by Recordati. The FDA approved the twice-daily subcutaneous form in 2012 for Cushing's disease when surgery is not an option or has failed, the first drug approved for that indication, and the monthly long-acting depot in 2014 for acromegaly inadequately controlled by surgery. It normalises cortisol in a minority and growth hormone and IGF-1 in a larger fraction of patients, and shrinks tumours in many.
Hyperglycaemia, from suppression of insulin and incretins, is the main side effect and often needs treatment. Beyond the pituitary, the phase 2 LUNA trial tested it alone and with everolimus in lung and thymic neuroendocrine tumours and found activity in each arm, without a placebo comparison. The pituitary tumours and lung neuroendocrine tumour pages name it.
1.Pasireotide binds Somatostatin receptor 2.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2012 | Cushing's disease when pituitary surgery is not an option or has not been curative |
| US | 2014 | Acromegaly inadequately controlled by surgery or for whom surgery is not an option (long-acting depot) |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Pasireotide" OR ABSTRACT:"Pasireotide" OR TITLE:"Signifor" OR ABSTRACT:"Signifor" OR TITLE:"Signifor LAR" OR ABSTRACT:"Signifor LAR" OR TITLE:"SOM230" OR ABSTRACT:"SOM230") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pasireotide, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialRADIANT-3 and RADIANT-4
Shares Everolimus, Lung neuroendocrine tumours (typical and atypical carcinoid).
- TrialCOMPETE
Shares Everolimus, Somatostatin receptor 2.
- IndicationMultiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)
Shares Everolimus, Somatostatin receptor 2.
- IndicationGrade 3 well-differentiated neuroendocrine tumour
Shares Everolimus, Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
- CompanyPerspective Therapeutics
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
- IndicationSmall intestinal neuroendocrine tumours
Shares Everolimus, Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
- IndicationPancreatic neuroendocrine tumours
Shares Everolimus, Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
- AgentGallium-68 DOTATATE (and Cu-64 DOTATATE)
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.